Literature DB >> 2416265

Serial immunological studies in multiple sclerosis patients treated systemically with human alpha interferon.

H S Panitch, G S Francis, C J Hooper, T C Merigan, K P Johnson.   

Abstract

A battery of immunological functions was studied over a 2-year period in conjunction with a placebo-controlled trial of natural human alpha interferon in patients with multiple sclerosis. IgG synthesis was increased both systemically and intrathecally by administration of interferon; however, there were only minor changes in cerebrospinal fluid oligoclonal bands. Levels of helper and suppressor T lymphocytes fluctuated independently of clinical exacerbations, although mean helper/suppressor ratios were higher in multiple sclerosis patients than in controls and increased further during interferon treatment. Cerebrospinal fluid myelin basic protein and antibodies to basic protein were not affected by exacerbations or by interferon administration. Circulating IgG antibodies induced by interferon treatment appeared to be directed at a non-interferon contaminant of the preparation. None of the assays was a consistent indicator of disease activity or of clinical response to interferon.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2416265     DOI: 10.1002/ana.410180404

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  6 in total

1.  Intravenous natural beta interferon treatment of chronic exacerbating-remitting multiple sclerosis: clinical response and MRI/CSF findings.

Authors:  M Huber; S Bamborschke; J Assheuer; W D Heiss
Journal:  J Neurol       Date:  1988-01       Impact factor: 4.849

2.  The effect of interferon-alpha on the ecto 5'-nucleotidase of human lymphoblastoid B-cell lines depends on the class of immunoglobulin secreted.

Authors:  S M Johnson
Journal:  Immunology       Date:  1991-09       Impact factor: 7.397

Review 3.  Mechanisms of action of interferon-beta in multiple sclerosis.

Authors:  B G Arnason; A Dayal; Z X Qu; M A Jensen; K Genç; A T Reder
Journal:  Springer Semin Immunopathol       Date:  1996

4.  Intraventricular interferon in a case of subacute sclerosing panencephalitis.

Authors:  A Boiardi; S M Baldini; A Sghirlanzoni; R Mancuso; F Corridori
Journal:  Ital J Neurol Sci       Date:  1987-06

Review 5.  The clinical use of cerebrospinal fluid studies in demyelinating neurological diseases.

Authors:  M G Harrington; P G Kennedy
Journal:  Postgrad Med J       Date:  1987-09       Impact factor: 2.401

Review 6.  Interferons in multiple sclerosis. A review of the evidence.

Authors:  H S Panitch
Journal:  Drugs       Date:  1992-12       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.